Effects of ZSET1446/ST101 on Cognitive Deficits and Amyloid β Deposition in the Senescence Accelerated Prone Mouse Brain

Journal of Pharmacological Sciences

Kenichi Saito¹  Yoshimasa Yamaguchi¹  Masataka Hino¹  Kentaro Takeda¹  Toshiyuki Matsuno¹ 

[1] Central Research Laboratory, Zenyaku Kogyo Co., Ltd., Japan

关键词: ZSET1446;    senescence accelerated prone mouse strain 8 (SAMP8);    object recognition test;    amyloid β;    grading score;   

DOI  :  10.1254/jphs.12036FP

学科分类：药学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(34)Cited-By(7)The senescence accelerated prone mouse strain 8 (SAMP8) develops age-related deficits in learning and memory. Effects of the azaindolizinone derivative ZSET1446/ST101, a newly synthesized cognitive enhancer, on cognitive impairment and deposition of amyloid β (Aβ) were assessed in the SAMP8. ZSET1446 was administered in drinking water at estimated doses of 0.002, 0.01, and 0.1 mg/kg per day from the age of 8 months. The SAMP8 at the age of 8 months showed cognitive impairment in a novel object recognition task compared with young SAMP8 at the age of 8 weeks. Further, grading scores were gradually increased from 9 to 12 months and Aβ-like immunoreactivity in the hippocampus was increased at the age of 10 months. ZSET1446 ameliorated cognitive deficits of SAMP8 after 4, 8, 12, and 16 weeks of treatment in a novel object recognition test. ZSET1446 also reduced grading scores of SAMP8 after 16 weeks of treatment. Further, 8-week treatment of ZSET1446 significantly reduced the total number of Aβ-positive granules in the hippocampus. These results suggest that ZSET1446 shows ameliorating effects on SAMP8 partly due to the suppression of an increase of Aβ-deposition in the hippocampus.

【 授权许可】

Unknown